Table 1. Characteristics of TEEWA study participants included in quantitative analysis.
| Characteristics (N = 568) | Median (Interquartile Range) or N (%) | |||
|---|---|---|---|---|
| Adherent participants (n = 293) |
Participants with suboptimal adherence (n = 275) |
All participants (n = 568) |
||
| Age (years) | 14.4 (13.1–16.0) | 14.3 (13.1–16.0) | 14.4 (13.1–16.0) | |
| Male | 124 (42.3) | 113 (41.1) | 237 (41.7) | |
| Pubertya | 198 (68.0) | 179 (65.1) | 377 (66.6) | |
| Geographic region | North | 173 (59.0) | 159 (57.8) | 332 (58.5) |
| Northeast | 30 (10.2) | 35 (12.7) | 65 (11.4) | |
| Center and South | 90 (30.7) | 81 (29.5) | 171 (30.1) | |
| Caregiver type | Biological parents | 110 (37.5) | 69 (25.1) | 179 (31.5) |
| Grandparents | 108 (36.9) | 105 (38.2) | 213 (37.5) | |
| Other family members | 75 (25.6) | 101 (36.7) | 176 (31.0) | |
| Orphan status | Both parents alive | 46 (15.7) | 32 (11.6) | 78 (13.7) |
| Mother died or unknown | 59 (20.1) | 48 (17.5) | 107 (18.8) | |
| Father died or unknown | 64 (21.8) | 48 (17.5) | 112 (19.7) | |
| Both died or unknown | 124 (42.3) | 147 (53.5) | 271 (47.7) | |
| Caregiver education | None | 47 (16.0) | 36 (13.1) | 83 (14.6) |
| Primary school | 191 (65.2) | 187 (68.0) | 378 (66.5) | |
| Secondary school and above | 55 (18.8) | 52 (18.9) | 107 (18.8) | |
| Suboptimal adherence (nonadherence by one or more of the three measures) | - | - | 275 (48.4) | |
| Self-reported missing dose in past 7 days | - | - | 197 (34.7) | |
| Suboptimal adherence rated by caregiver | - | - | 43 (7.6) | |
| Most recent viral load ≥ 1000 copies/ml | - | - | 101 (17.8) | |
| Age at HIV diagnosis (years) | 8.0 (6.0–11.0) | 8.0 (5.0–10.0) | 8.0 (5.0–10.0) | |
| Age at ART initiation (years) | 9.2 (7.1–11.0) | 8.9 (6.8–11.5) | 9.0 (7.0–11.2) | |
| Years on ART | 5.7 (4.0–7.0) | 6.0 (4.1–7.3) | 5.9 (4.0–7.1) | |
|
Type of ART |
Non nucleotide reverse transcriptase inhibitor (NNRTI)-based | 242 (82.6) | 178 (64.7) | 420 (73.9) |
| Protease Inhibitor (PI)-based | 41 (14.0) | 76 (27.6) | 117 (20.6) | |
| Dual PI | 8 (2.7) | 16 (5.8) | 24 (4.2) | |
| Treatment interruption or only dual/mono therapy | 2 (0.7) | 5 (1.8) | 7 (1.2) | |
| Most recent absolute CD4 | 701 (523–910) | 558 (350–737) | 635 (441–859) | |
| Most recent CD4%b | 27 (22–32) | 23 (16–23) | 25 (19–30) | |
| Most recent VL | 40 (40–50) | 50 (40–7425) | 40 (40–80) | |
| Time from most recent CD 4 to interview (months)c | 5 (3–8) | 5 (3–7) | 5 (3–8) | |
| Time from most recent VL to interview(months)d | 8 (4–12) | 6 (3–11) | 7 (4–12) | |
| Presence of side effects | 35 (11.9) | 39 (14.2) | 74 (13.0) | |
| Frequency of daily intakee | 1 | 4 (1.5) | 8 (3.1) | 12 (2.3) |
| 2 | 257 (95.5) | 241 (93.8) | 498 (94.7) | |
| ≥ 3 | 8 (3.0) | 8 (3.1) | 16 (3.0) | |
| Number of daily tabletsf | 2.0 (2.0–6.0) 4.1 (mean) |
4.0 (2.0–7.0) 4.5 (mean) |
3.0 (2.0–7.0) 4.3 (mean) |
|
a. 2 missing values
b. 1 missing value
c. 1 missing value
d. 1 missing value
e. 42 missing values
f. 56 missing values.
Median (Interquartile Range) is presented for continuous variables, N (%) for categorical variables.